S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
Log in
NASDAQ:CLSN

Celsion Stock Forecast, Price & News

$0.57
-0.05 (-8.00 %)
(As of 10/19/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.56
Now: $0.57
$0.62
50-Day Range
$0.63
MA: $0.77
$1.02
52-Week Range
$0.56
Now: $0.57
$6.50
Volume1.20 million shs
Average Volume1.59 million shs
Market Capitalization$20.78 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Read More
Celsion logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSN
CUSIPN/A
Phone609-896-9100
Employees29

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$0.63 per share

Profitability

Net Income$-16,850,000.00
Net Margins-3,795.80%

Miscellaneous

Market Cap$20.78 million
Next Earnings Date11/12/2020 (Estimated)
OptionableOptionable
$0.57
-0.05 (-8.00 %)
(As of 10/19/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Celsion (NASDAQ:CLSN) Frequently Asked Questions

How has Celsion's stock price been impacted by COVID-19?

Celsion's stock was trading at $0.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CLSN stock has decreased by 41.9% and is now trading at $0.5747.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Celsion?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Celsion
.

When is Celsion's next earnings date?

Celsion is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Celsion
.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) announced its quarterly earnings data on Friday, August, 14th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.04. The biotechnology company had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative net margin of 3,795.80% and a negative return on equity of 107.78%.
View Celsion's earnings history
.

When did Celsion's stock split? How did Celsion's stock split work?

Celsion's stock reverse split on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CLSN?

2 equities research analysts have issued 12-month price targets for Celsion's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Celsion's share price to reach $4.00 in the next year. This suggests a possible upside of 596.0% from the stock's current price.
View analysts' price targets for Celsion
.

Who are some of Celsion's key competitors?

What other stocks do shareholders of Celsion own?

Who are Celsion's key executives?

Celsion's management team includes the following people:
  • Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 69, Pay $786.91k)
  • Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 63, Pay $455.92k)
  • Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 60, Pay $409.32k)
  • Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 61, Pay $505.98k)
  • Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 62)

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $0.57.

How big of a company is Celsion?

Celsion has a market capitalization of $20.78 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Celsion employs 29 workers across the globe.

What is Celsion's official website?

The official website for Celsion is www.celsion.com.

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]

This page was last updated on 10/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.